Amino acid (aa) mutations in the interferon-sensitivity determining region (ISDR) (aa position 237-276 of the nonstructural region 5A [NS5A] protein consisting of 447 amino acids) of hepatitis C virus (HCV) are related to increased interferon sensitivity and low viral load, but its mechanism has not
Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles
โ Scribed by Wagane J. A. Benga; Sophie E. Krieger; Maria Dimitrova; Mirjam B. Zeisel; Marie Parnot; Joachim Lupberger; Eberhard Hildt; Guangxiang Luo; John McLauchlan; Thomas F. Baumert; Catherine Schuster
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 812 KB
- Volume
- 51
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
โฆ Synopsis
Chronic hepatitis C virus (HCV) infection is a major cause of liver disease worldwide. Restriction of HCV infection to human hepatocytes suggests that liver-specific host factors play a role in the viral life cycle. Using a yeast-two-hybrid system, we identified apolipoprotein E (apoE) as a liver-derived host factor specifically interacting with HCV nonstructural protein 5A (NS5A) but not with other viral proteins. The relevance of apoE-NS5A interaction for viral infection was confirmed by co-immunoprecipitation and co-localization studies of apoE and NS5A in an infectious HCV cell culture model system. Silencing apoE expression resulted in marked inhibition of infectious particle production without affecting viral entry and replication. Analysis of particle production in liver-derived cells with silenced apoE expression showed impairment of infectious particle assembly and release. The functional relevance of the apoE-NS5A interaction for production of viral particles was supported by loss or decrease of apoE-NS5A binding in assembly-defective viral mutants.
Conclusion:
These results suggest that recruitment of apoe by ns5a is important for viral assembly and release of infectious viral particles. these findings have important implications for understanding the hcv life cycle and the development of novel antiviral strategies targeting hcv-lipoprotein interaction.
๐ SIMILAR VOLUMES
Abbreviations: AE, adverse event; AUC, area under the plasma concentration time curve; AUC (TAU) , AUC over 12-hour dosing interval for 30 mg twice daily; C min , minimum observed plasma concentration; C max , maximum observed plasma concentration; C trough , trough concentrations; CLT/F, apparent t
The NS5A replication complex inhibitor, BMS-790052, inhibits hepatitis C virus (HCV) replication with picomolar potency in preclinical assays. This potency translated in vivo to a substantial antiviral effect in a single-ascending dose study and a 14-day multiple-ascending dose (MAD) monotherapy stu